Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

MAD2L2 Promotes NHEJ at DSBs and Telomeres via 5′ End Resection Inhibition

DOI: 10.1158/2159-8290.CD-RW2015-060 Published May 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • Major finding: MAD2L2 promotes NHEJ at exposed DNA ends by inhibiting CTIP-dependent 5′ end resection.

  • Clinical relevance: Restoration of HR via MAD2L2 loss may drive PARP inhibitor resistance in BRCA1-deficient cancers.

  • Impact: MAD2L2 regulates DNA repair choices downstream of 53BP1 and RIF1 and independent of DNA Polζ.

Figure1

Proper regulation of error-free homologous recombination (HR)–mediated repair at DNA double-strand breaks (DSB) and telomeres is required for genomic stability and is orchestrated by a complex network of proteins including BRCA1. Defects in HR activity fuel the acquisition of genomic alterations and confer dependency on parallel DNA repair pathways that have been targeted using PARP1 inhibitors. To identify regulators of telomere-induced genomic instability and nonhomologous end-joining (NHEJ)–dependent repair of uncapped telomeres, Boersma, Moatti, and colleagues performed a functional genetic screen. Suppression of mitotic arrest deficient-like 2 (MAD2L2, also known as REV7) prevented telomere fusion and enhanced cell survival. Mechanistically, MAD2L2 was recruited to exposed telomeres and sites of irradiation-induced DSBs and promoted NHEJ activity in multiple contexts by inhibiting CtBP-interacting protein (CTIP)–dependent and exonuclease 1–dependent 5′ DNA end resection independent of PAX-interacting protein 1 and the other components of DNA polymerase ζ (Polζ), REV1 and REV3. In a parallel study, Xu, Chapman, Brandsma, and colleagues identified MAD2L2 suppression as a mediator of resistance to the PARP1 inhibitor olaparib in BRCA1-deficient tumor cells both in vitro and in vivo. MAD2L2 depletion promoted olaparib resistance by increasing CTIP-dependent DNA end resection, restoring HR activity in BRCA1-deficient cells independent of the Polζ-associated function in translesion synthesis. Importantly, both groups found that MAD2L2 recruitment to DSBs was dependent on ATM kinase activity, histone H2AX, mediator of DNA damage checkpoint 1, ring finger protein 8 (RNF8), RNF168, and p53-binding protein 1 (53BP1), with Boersma, Moatti, and colleagues also showing dependence on RAP-interacting factor 1 (RIF1). In addition, both groups found that MAD2L2 loss inhibited NHEJ activity and decreased class switch recombination, similar to the effects of 53BP1 ablation. Together, these data highlight a critical role for MAD2L2 in the regulation of DNA repair pathway decisions downstream of 53BP1 and suggest that MAD2L2 loss may compromise genomic integrity.

Boersma V, Moatti N, Segura-Bayona S, Peuscher MH, van der Torre J, Wevers BA, et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection. Nature 2015 Mar 23 [Epub ahead of print].

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015 Mar 23 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery Science Writers. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (5)
May 2015
Volume 5, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MAD2L2 Promotes NHEJ at DSBs and Telomeres via 5′ End Resection Inhibition
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MAD2L2 Promotes NHEJ at DSBs and Telomeres via 5′ End Resection Inhibition
Cancer Discov May 1 2015 (5) (5) 462; DOI: 10.1158/2159-8290.CD-RW2015-060

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MAD2L2 Promotes NHEJ at DSBs and Telomeres via 5′ End Resection Inhibition
Cancer Discov May 1 2015 (5) (5) 462; DOI: 10.1158/2159-8290.CD-RW2015-060
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • T-cell Receptor–Engineered T Cells Show Efficacy in HPV+ Carcinomas
  • Germline Genetic Variation Modulates Tumor Immune Microenvironment
  • Computational Analysis Finds Protein Stability–Related Cancer Mutations
Show more Research Watch

DNA Repair

  • Histone Methylation Connects DNA Repair to Metabolism in Cancer Cells
  • Release of Paused Pol II Induces Double-Strand Breaks in Normal Cells
  • UBQLN4 Regulates DNA Repair Pathway Choice
Show more DNA Repair
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement